Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy | Zendy

Paula K. Schweitzer | Zendy; Kingman P. Strohl | Zendy; Geert Mayer | Zendy; Russell Rosenberg | Zendy; Patricia Chandler | Zendy; Michelle Baladi | Zendy; Lawrence Lee | Zendy; Atul Malhotra | Zendy

Open Access

Effects of solriamfetol in a long-term trial of participants with obstructive sleep apnea who are adherent or nonadherent to airway therapy

Author(s) -

Paula K. Schweitzer,

Kingman P. Strohl,

Geert Mayer,

Russell Rosenberg,

Patricia Chandler,

Michelle Baladi,

Lawrence Lee,

Atul Malhotra

Publication year - 2020

Publication title -

journal of clinical sleep medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.529

H-Index - 92

eISSN - 1550-9397

pISSN - 1550-9389

DOI - 10.5664/jcsm.8992

Subject(s) - medicine , obstructive sleep apnea , continuous positive airway pressure , sleep (system call) , airway , term (time) , sleep apnea , apnea , randomized controlled trial , polysomnography , anesthesia , physical therapy , physics , quantum mechanics , computer science , operating system

Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the United States and European Union to treat excessive daytime sleepiness in patients with obstructive sleep apnea (OSA) (37.5-150 mg/day) and narcolepsy (75-150 mg/day). This analysis evaluated solriamfetol's efficacy in subgroups of participants with OSA who were adherent or nonadherent to primary OSA therapy at baseline and examined whether solriamfetol affected the use of primary therapy in an open-label extension trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research